AbbVie Statistics

Total Valuation

AbbVie has a market cap or net worth of EUR 297.86 billion. The enterprise value is 359.38 billion.

Market Cap	297.86B
Enterprise Value	359.38B

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	Jan 15, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.76B

Valuation Ratios

The trailing PE ratio is 65.38.

PE Ratio	65.38
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.43, with an EV/FCF ratio of 25.66.

EV / Earnings	78.89
EV / Sales	6.74
EV / EBITDA	14.43
EV / EBIT	21.68
EV / FCF	25.66

Financial Position

The company has a current ratio of 0.65, with a Debt / Equity ratio of 11.75.

Current Ratio	0.65
Quick Ratio	0.44
Debt / Equity	11.75
Debt / EBITDA	2.75
Debt / FCF	4.57
Interest Coverage	6.47

Financial Efficiency

Return on equity (ROE) is 56.41% and return on invested capital (ROIC) is 14.32%.

Return on Equity (ROE)	56.41%
Return on Assets (ROA)	7.72%
Return on Capital (ROIC)	14.32%
Revenue Per Employee	995,818
Profits Per Employee	91,112
Employee Count	50,000
Asset Turnover	0.40
Inventory Turnover	3.91

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.79% in the last 52 weeks. The beta is 0.62, so AbbVie's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+19.79%
50-Day Moving Average	171.89
200-Day Moving Average	165.23
Relative Strength Index (RSI)	48.91
Average Volume (20 Days)	5,203

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.10

Income Statement

In the last 12 months, AbbVie had revenue of EUR 49.79 billion and earned 4.56 billion in profits. Earnings per share was 2.57.

Revenue	49.79B
Gross Profit	35.02B
Operating Income	15.48B
Pretax Income	6.45B
Net Income	4.56B
EBITDA	22.98B
EBIT	15.48B
Earnings Per Share (EPS)	2.57

Full Income Statement

Balance Sheet

The company has 6.53 billion in cash and 63.95 billion in debt, giving a net cash position of -57.42 billion.

Cash & Cash Equivalents	6.53B
Total Debt	63.95B
Net Cash	-57.42B
Net Cash Per Share	n/a
Equity (Book Value)	5.44B
Book Value Per Share	3.06
Working Capital	-13.70B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 14.80 billion and capital expenditures -796.18 million, giving a free cash flow of 14.01 billion.

Operating Cash Flow	14.80B
Capital Expenditures	-796.18M
Free Cash Flow	14.01B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 70.33%, with operating and profit margins of 31.10% and 9.22%.

Gross Margin	70.33%
Operating Margin	31.10%
Pretax Margin	12.96%
Profit Margin	9.22%
EBITDA Margin	46.15%
EBIT Margin	31.10%
FCF Margin	28.13%

Dividends & Yields

This stock pays an annual dividend of 5.70, which amounts to a dividend yield of 3.44%.

Dividend Per Share	5.70
Dividend Yield	3.44%
Dividend Growth (YoY)	4.68%
Years of Dividend Growth	5
Payout Ratio	212.79%
Buyback Yield	0.07%
Shareholder Yield	3.51%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AbbVie has an Altman Z-Score of 1.9. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.9
Piotroski F-Score	n/a